---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000033"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:18:39.625894+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics adopts poison pill and launches strategic review including potential sale

## Summary
- Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.
- Adopted limited-duration rights plan (10% threshold, 15% for passive institutional) expiring April 9, 2026.
- Rights plan triggered by an individual investor that disclosed 11.2% ownership as of April 6, 2025.
- Dividend of one right per common share for stockholders of record on April 24, 2025.
- Goldman Sachs & Co. LLC engaged as financial advisor; Cooley LLP as legal counsel.

## SEC filing metadata
- accession: 0001664710-25-000033
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/0001664710-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/kros-20250409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000033
- JSON: https://secwatch.observer/filing/0001664710-25-000033.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.